|Discription||Erlotinib is an epidermal growth factor receptor inhibitor (EGFR inhibitor). Erlotinib HCl was approved. Erlotinib binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. For the signal to be transmitted, two EGFR molecules need to come together to form a homodimer. These then use the molecule of ATP to trans-phosphorylate each other on tyrosine residues, which generates phosphotyrosine residues, recruiting the phosphotyrosine-binding proteins to EGFR to assemble protein complexes that transduce signal cascades to the nucleus or activate other cellular biochemical processes. When erlotinib binds to EGFR, formation of phosphotyrosine residues in EGFR is not possible and the signal cascades are not initiated.|
|Synonyms||CP-358,774, CP-358774, CP358774, OSI-774, OSI 774, OSI774, Erlotinib free base.|
Store lyophilized at -20ºC, keep desiccated.
|In vitro (25°C)||DMSO||68 mg/mL (172.83 mM)|
|Ethanol||Warmed: 13 mg/mL|
|In vivo||5% DMSO+30% PEG 300+5% Tween 80+ddH2O||5 mg/mL|
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||25.42 mL||127.08 mL||254.17 mL|
|0.5 mM||5.08 mL||25.42 mL||50.83 mL|
|1 mM||2.54 mL||12.71 mL||25.42 mL|
|5 mM||0.51 mL||2.54 mL||5.08 mL|
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2